A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder

Deep brain stimulation (DBS) has been proposed for severe, chronic, treatment-refractory obsessive-compulsive disorder (OCD) patients. Although serious adverse events can occur, only a few studies report on the safety profile of DBS for psychiatric disorders. In a prospective, open-label, interventional multi-center study, we examined the safety and efficacy of electrical stimulation in 30 patients with DBS electrodes bilaterally implanted in the anterior limb of the internal capsule. Safety, efficacy, and functionality assessments were performed at 3, 6, and 12 months post implant. An independent Clinical Events Committee classified and coded all adverse events (AEs) according to EN ISO14155:2011. All patients experienced AEs (195 in total), with the majority of these being mild (52% of all AEs) or moderate (37%). Median time to resolution was 22 days for all AEs and the etiology with the highest AE incidence was 'programming/stimulation' (in 26 patients), followed by 'New illness, injury, condition' (13 patients) and 'pre-existing condition, worsening or exacerbation' (11 patients). Sixteen patients reported a total of 36 serious AEs (eight of them in one single patient), mainly transient anxiety and affective symptoms worsening (20 SAEs). Regarding efficacy measures, Y-BOCS reduction was 42% at 12 months and the responder rate was 60%. Improvements in GAF, CGI, and EuroQol-5D index scores were also observed. In sum, although some severe AEs occurred, most AEs were mild or moderate, transient and related to programming/stimulation and tended to resolve by adjustment of stimulation. In a severely treatment-resistant population, this open-label study supports that the potential benefits outweigh the potential risks of DBS

Dual task performance of working memory and postural control in major depressive disorder

status: publishe

The Penn State Worry Questionnaire – Past Day: Development and validation of a measure assessing daily levels of worry

Based on the widely used Penn State Worry Questionnaire for trait worry, a scale was developed to measure the level of worry experienced during the past 24 h. This instrument, the Penn State Worry Questionnaire-Past Day (PSWQ-PD), was administered to a student sample and two clinical samples. The PSWQ-PD demonstrated high internal consistency, good convergent validity and adequate test-retest reliability. A confirmatory factor analysis revealed that a unifactorial solution provided the best fit. Moreover, it was shown that the PSWQ-PD is a more state-like worry measure than the original PSWQ. The PSWQ-PD is a promising, brief tool for daily worry assessment, which is apt for frequent administration. © Springer Science+Business Media, LLC 2011.status: publishe

Reduced autobiographical memory specificity and rumination in predicting the course of depression

Reduced autobiographical memory (AM) specificity is a known vulnerability factor for depression. AM specificity was investigated as a predictor of depression with the Autobiographical Memory Test (J. M. G. Williams & K. Broadbent, 1986). When baseline depression scores were partialed, reduced AM specificity to negative cue words predicted higher levels of depression at 7-month follow-up. Once rumination was taken into account by means of the Rumination on Sadness Scale (M. Conway, P. A. R. Csank, S. L. Holm, & C. K. Blake, 2000), AM specificity no longer predicted depression, suggesting that the predictive value of AM specificity observed in previous studies might be-at least partly-explained as an effect of rumination. Further mediation analyses indeed revealed support for rumination as a mediator of the relation between reduced AM specificity and poor outcome of depression.status: publishe

Reduced autobiographical memory specificity and rumination in predicting the course of depression.

Reduced autobiographical memory (AM) specificity is a known vulnerability factor for depression. AM specificity was investigated as a predictor of depression with the Autobiographical Memory Test (J. M. G. Williams and K. Broadbent, 1986). When baseline depression scores were partialed, reduced AM specificity to negative cue words predicted higher levels of depression at 7-month follow-up. Once rumination was taken into account by means of the Rumination on Sadness Scale (M. Conway, P. A. R. Csank, S. L. Holm, and C. K. Blake, 2000), AM specificity no longer predicted depression, suggesting that the predictive value of AM specificity observed in previous studies might be--at least partly--explained as an effect of rumination. Further mediation analyses indeed revealed support for rumination as a mediator of the relation between reduced AM specificity and poor outcome of depression

A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder.

Deep brain stimulation (DBS) has been proposed for severe, chronic, treatment-refractory obsessive-compulsive disorder (OCD) patients. Although serious adverse events can occur, only a few studies report on the safety profile of DBS for psychiatric disorders. In a prospective, open-label, interventional multi-center study, we examined the safety and efficacy of electrical stimulation in 30 patients with DBS electrodes bilaterally implanted in the anterior limb of the internal capsule. Safety, efficacy, and functionality assessments were performed at 3, 6, and 12 months post implant. An independent Clinical Events Committee classified and coded all adverse events (AEs) according to EN ISO14155:2011. All patients experienced AEs (195 in total), with the majority of these being mild (52% of all AEs) or moderate (37%). Median time to resolution was 22 days for all AEs and the etiology with the highest AE incidence was 'programming/stimulation' (in 26 patients), followed by 'New illness, injury, condition' (13 patients) and 'pre-existing condition, worsening or exacerbation' (11 patients). Sixteen patients reported a total of 36 serious AEs (eight of them in one single patient), mainly transient anxiety and affective symptoms worsening (20 SAEs). Regarding efficacy measures, Y-BOCS reduction was 42% at 12 months and the responder rate was 60%. Improvements in GAF, CGI, and EuroQol-5D index scores were also observed. In sum, although some severe AEs occurred, most AEs were mild or moderate, transient and related to programming/stimulation and tended to resolve by adjustment of stimulation. In a severely treatment-resistant population, this open-label study supports that the potential benefits outweigh the potential risks of DBS.status: Published onlin

A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder.

Deep brain stimulation (DBS) has been proposed for severe, chronic, treatment-refractory obsessive-compulsive disorder (OCD) patients. Although serious adverse events can occur, only a few studies report on the safety profile of DBS for psychiatric disorders. In a prospective, open-label, interventional multi-center study, we examined the safety and efficacy of electrical stimulation in 30 patients with DBS electrodes bilaterally implanted in the anterior limb of the internal capsule. Safety, efficacy, and functionality assessments were performed at 3, 6, and 12 months post implant. An independent Clinical Events Committee classified and coded all adverse events (AEs) according to EN ISO14155:2011. All patients experienced AEs (195 in total), with the majority of these being mild (52% of all AEs) or moderate (37%). Median time to resolution was 22 days for all AEs and the etiology with the highest AE incidence was 'programming/stimulation' (in 26 patients), followed by 'New illness, injury, condition' (13 patients) and 'pre-existing condition, worsening or exacerbation' (11 patients). Sixteen patients reported a total of 36 serious AEs (eight of them in one single patient), mainly transient anxiety and affective symptoms worsening (20 SAEs). Regarding efficacy measures, Y-BOCS reduction was 42% at 12 months and the responder rate was 60%. Improvements in GAF, CGI, and EuroQol-5D index scores were also observed. In sum, although some severe AEs occurred, most AEs were mild or moderate, transient and related to programming/stimulation and tended to resolve by adjustment of stimulation. In a severely treatment-resistant population, this open-label study supports that the potential benefits outweigh the potential risks of DBS